Bot MD
+80%
est. 2Y upside i
AI Clinical Assistant for Doctors
Rank
#588
Sector
Healthtech
Est. Liquidity
~4Y
Data Quality
Data: LowDespite a low entry valuation, the severe preference overhang (97%) and stale mark from 2021 make the equity upside for a new employee modest (expected ~80% over 2 years).
Last updated: July 19, 2026
Bot MD achieves category leadership in Southeast Asian healthtech, with an IPO window opening in 2027. Revenue reaches $4.5M by 2028, and the market applies a 5x multiple, valuing equity at $22.5M for a 211% upside net of dilution.
The company continues steady growth in its niche, reaching $4.5M revenue by 2028. A 3x multiple in line with mature healthtech peers implies a $13.5M valuation, yielding 78.5% upside after dilution.
Growth slows as large incumbents (Google, Microsoft) or EHR vendors integrate competing AI features. Revenue reaches only $4.5M but the multiple compresses to 1.5x, implying $6.75M valuation, a -20.7% net loss for common after dilution.
Preference Stack Risk
severeFunding Intensity
97%Total preferred liquidation preference of $6.6M represents 97% of current valuation, leaving minimal common equity value.
Dilution Risk
highThe company hasn't raised since 2021; with $2.3M revenue and 27 employees, additional funding is likely within 2 years, diluting common by ~20%.
Secondary Liquidity
noneNo secondary market activity detected; no tender offers.
Questions to Ask at the Interview
Strategic questions based on Bot MD's data — designed to show you've done your homework.
- 1
“How does Bot MD plan to compete with AI capabilities from major cloud providers?”
- 2
“What is the company's go-to-market strategy for expanding beyond Southeast Asia?”
- 3
“Given the 5-year gap since the last funding round, what is the company's cash runway and plans for future fundraising?”
Community
Valuation Sentiment
Our model estimates +80% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.